|
|
Vaccine Detail
|
rCMV- EBOV |
| Vaccine Information |
- Vaccine Name: rCMV- EBOV
- Target Pathogen: Ebola virus
- Target Disease: Ebola hemorrhagic fever
- Vaccine Ontology ID: VO_0004717
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Baboon
- NP from Zaire Ebola virus
gene engineering:
- Type: Recombinant protein preparation
- Description: A mouse CMV (MCMV) vector expressing a CD8+ T cell epitope from the nucleoprotein (NP) of Zaire ebolavirus (ZEBOV) (MCMV/ZEBOV-NP(CTL)) (Tsuda et al., 2011).
- Detailed Gene Information: Click Here.
- Vector:
- Preparation: A mouse CMV (MCMV) vector expressing a CD8+ T cell epitope from the nucleoprotein (NP) of Zaire ebolavirus (ZEBOV) (MCMV/ZEBOV-NP(CTL)) (Tsuda et al., 2011).
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Mouse Response
- Vaccination Protocol: Mice were vaccinated with rCMV- EBOV (Tsuda et al., 2011).
- Vaccine Immune Response Type: VO_0003057
- Challenge Protocol: Mice were challenged with a lethal dose of ZEBOV (Tsuda et al., 2011).
- Efficacy: The vaccine induced high levels of long-lasting (>8 months) CD8+ T cells against ZEBOV NP in mice. Importantly, all vaccinated animals were protected against lethal ZEBOV challenge (Tsuda et al., 2011).
|
| References |
Tsuda et al., 2011: Tsuda Y, Caposio P, Parkins CJ, Botto S, Messaoudi I, Cicin-Sain L, Feldmann H, Jarvis MA. A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. PLoS neglected tropical diseases. 2011; 5(8); e1275. [PubMed: 21858240].
|
|
